Industry
Biotechnology
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Loading...
Open
1.21
Mkt cap
6.2M
Volume
238K
High
1.23
P/E Ratio
-0.44
52-wk high
2.67
Low
1.03
Div yield
N/A
52-wk low
1.03
Portfolio Pulse from
December 17, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 11:36 am
Portfolio Pulse from Benzinga Insights
September 30, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
September 30, 2024 | 2:18 pm
Portfolio Pulse from Benzinga Insights
September 27, 2024 | 4:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.